10-Q: Nuwellis Reports Q2 Loss, Strategic Shifts Amid Nasdaq Scrutiny

Nuwellis, Inc. reported a wider net loss in Q2 2025, implemented a reverse stock split, and exited international operations while terminating a clinical trial to focus on core U.S. markets.

Summary

• Net sales for the three months ended June 30, 2025, decreased by 21.4% to $1.725 million from $2.194 million in the prior year, primarily due to a 21% decrease in circuit sales and lower console sales, partly attributed to a temporary $400,000 backorder from a sterilization vendor issue.
• Net sales for the six months ended June 30, 2025, decreased by 10.4% to $3.629 million from $4.051 million in the prior year, driven by a 9% decrease in circuit sales, console sales, and international sales.
• Gross profit margin declined to 55.5% for Q2 2025 (from 67.2% in Q2 2024) and 55.8% for the six months ended June 30, 2025 (from 65.8% in the prior year), mainly due to unfavorable manufacturing variances and under-absorption of fixed overhead from lower production volumes.
• Net loss for Q2 2025 widened to $12.553 million from $7.725 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, increased to $15.567 million from $12.055 million in the prior year.
• Cash and cash equivalents decreased to $4.450 million as of June 30, 2025, from $5.095 million at December 31, 2024.
• The company completed a public offering on June 10, 2025, raising approximately $5.0 million in gross proceeds, involving common stock and warrants.
• A 1-for-42 reverse stock split was approved on June 19, 2025, and became effective on July 3, 2025, to address Nasdaq's minimum bid price requirement.
• The REVERSE-HF clinical trial was terminated on July 17, 2025, expected to save approximately $4.0 million over 2.5 years, to reallocate resources to outpatient heart failure, pediatric, and critical care.
• Nuwellis decided to exit international operations on August 7, 2025, to focus exclusively on the U.S. market.
• The company's disclosure controls and procedures were deemed not effective as of June 30, 2025, due to two material weaknesses in internal controls over financial reporting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in sales and gross profit, widening net losses, and a 'going concern' warning. While strategic realignments and a recent capital raise address immediate Nasdaq compliance and cash burn, the underlying financial performance and internal control weaknesses remain substantial concerns. The large financing expense from the warrant valuation also weighs heavily.

Positives

• Net cash used in operating activities for the six months ended June 30, 2025, decreased to $4.633 million from $5.616 million in the prior year, indicating a reduced cash burn rate.
• The June 2025 public offering successfully raised approximately $5.0 million in gross proceeds, providing additional capital.
• The 1-for-42 reverse stock split and subsequent reclassification of Series A and B warrants to equity helped the company regain compliance with Nasdaq's minimum bid price and stockholders' equity requirements, avoiding delisting.
• Termination of the REVERSE-HF clinical trial is expected to save approximately $4.0 million over 2.5 years, allowing for strategic reallocation of resources.
• Exiting international operations to focus on the U.S. market aims to streamline operations and invest in areas with stronger growth and clinical demand.

Negatives

• Net sales decreased by 21.4% in Q2 2025 and 10.4% for the six months ended June 30, 2025, compared to the prior year periods.
• Gross profit margin significantly declined from 67.2% to 55.5% in Q2 2025, primarily due to unfavorable manufacturing variances and under-absorption of fixed overhead.
• Net loss widened to $12.553 million in Q2 2025 from $7.725 million in Q2 2024, and to $15.567 million for the six months ended June 30, 2025, from $12.055 million in the prior year.
• The company had an accumulated deficit of $314.4 million as of June 30, 2025, and expects to incur losses for the foreseeable future.
• A 'going concern' warning is present, indicating substantial doubt about the company's ability to continue operations for at least the next twelve months without additional funding.
• The valuation of warrants from the June 2025 offering ($14.5 million) significantly exceeded the gross proceeds ($5.0 million), resulting in a $9.5 million 'Day 1 interest' recorded as financing expense.
• Disclosure controls and procedures were deemed 'not effective' as of June 30, 2025, due to identified material weaknesses in internal controls over financial reporting.

Risks

• The company faces substantial doubt about its ability to continue as a going concern through at least twelve months from the filing date, requiring additional capital.
• Risk of Nasdaq delisting if the company fails to maintain compliance with minimum stockholders' equity or other listing requirements, despite recent actions.
• Potential for substantial civil and criminal penalties if the company fails to comply with federal and state laws regarding off-label use of its Aquadex System, which is used off-label for patients weighing less than 20 kg, including neonates.
• Changes to U.S. tariff and import/export regulations could negatively impact suppliers and/or service providers, increasing costs for raw materials (some sourced from China) and parts.
• Changes in U.S. federal government funding for the FDA and other agencies, including potential restructuring or budget cuts, could hinder product review and approval processes.
• Dependence on a material sole source supplier for raw materials, including a fully validated third-party sterilizer, poses a risk of supply interruption and production delays.

Future Outlook

The company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in sales and marketing, inventory, clinical research, and new product development. Existing capital resources are believed to be sufficient to support operations into the fourth quarter of 2025, but additional capital will be sought through debt, equity, or a combination thereof. The company anticipates saving approximately $4.0 million over the next 2.5 years by terminating the REVERSE-HF clinical trial and will focus resources on outpatient heart failure, pediatric, and critical care applications in the U.S. market.

Management Comments

• "We expect to incur additional losses in the near-term as we grow the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, investing in clinical research and new product development, and complying with the requirements related to being a U.S. public company."
• "To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System."
• "We believe that our existing capital resources will be sufficient to support our operating plan into the fourth quarter of 2025."
• "The Company will seek to raise additional capital to support its growth or other strategic initiatives through debt, equity, or a combination thereof."
• "This decision [to terminate REVERSE-HF clinical trial] reflects the Company’s strategic commitment to prioritize resources in areas demonstrating the greatest potential for patient impact and business growth—namely, outpatient heart failure, pediatric, and critical care."
• "This strategic realignment [exiting international operations] supports Nuwellis’ core business strategy: investing in the markets driving revenue growth."

Industry Context

Nuwellis operates in the medical technology sector, specifically focusing on ultrafiltration therapy for fluid overload. The strategic shift to prioritize U.S. markets and specific applications (outpatient heart failure, pediatric, critical care) aligns with a common industry trend for smaller medical device companies to focus resources on high-growth or high-margin niches rather than broad, capital-intensive clinical trials or international expansion. The challenges with Nasdaq listing and the need for frequent capital raises highlight the difficulties faced by microcap medical technology companies in securing sustained funding and achieving profitability, especially when product adoption is still expanding.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• None reported in the filing.

Related Party Transactions

• On June 9, 2025, 100 shares of Series F Preferred Stock owned by CEO John L. Erb were exchanged for Series F-1 Preferred Shares, and 66 of these Series F-1 shares were subsequently converted into 26,191 shares of common stock.

Stakeholder Impact

• **Shareholders:** Experienced significant dilution from recent offerings and reverse stock splits. Face ongoing risk of delisting, further dilution from future capital raises, and volatility due to financial instability and internal control weaknesses. The 'going concern' warning is a major concern.
• **Employees:** Salaries for senior management were reduced in 2024, and 401(k) match was temporarily suspended, though both were later restored. The strategic realignments (trial termination, international exit) could impact job roles or future growth opportunities in those areas.
• **Customers:** Potential impact from the temporary backorder of circuit revenue due to sterilization vendor issues. The focus on U.S. markets and specific applications may lead to improved service or product availability in those areas, but a reduction in international support.
• **Creditors:** The 'going concern' warning and accumulated deficit indicate elevated risk, potentially affecting terms for future debt financing.

Next Steps

• Continue efforts to expand adoption and market acceptance of the Aquadex System, particularly in outpatient heart failure, pediatric, and critical care applications in the U.S. market.
• Seek additional capital through debt, equity, or a combination thereof to support growth and strategic initiatives beyond Q4 2025.
• Actively monitor compliance with Nasdaq listing standards, especially the stockholders' equity requirement, and consider options to resolve any future deficiencies.
• Perform additional analyses, reconciliations, and remediations to address the identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by declining sales, widening net losses, a substantial accumulated deficit, and a 'going concern' warning. While recent capital raises and reverse stock splits temporarily addressed Nasdaq listing issues, these are largely cosmetic and do not resolve the fundamental operational and profitability challenges. The significant 'Day 1 interest' expense from the warrant valuation highlights unfavorable financing terms. Furthermore, the disclosure of 'not effective' internal controls over financial reporting indicates serious governance and operational deficiencies. Strategic shifts like trial termination and international exit, while aimed at efficiency, underscore the company's precarious position. Given the high risk of further dilution, potential delisting, and a lack of clear path to sustained profitability, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Medical Technology, Fluid Overload, Aquadex SmartFlow, Ultrafiltration Therapy, SEC Filing, Nasdaq Compliance, Reverse Stock Split, Clinical Trial Termination, International Operations Exit, Capital Raise, Going Concern, Financial Performance, Q2 2025 Results, Medical Device, Corporate Governance